New injection route, same Keytruda power: what Merck’s subcutaneous option means for patients

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/15/2026 at 8:30 PM ET. Details in the imprint.

Merck & Co. is advancing a subcutaneous formulation of its blockbuster cancer drug Keytruda (pembrolizumab), positioning the under-the-skin injection as a more convenient alternative to the existing intravenous infusion for patients and oncology clinics. In recent company updates, Merck has highlighted that the subcutaneous version is designed to deliver the same active antibody as IV Keytruda while dramatically shortening administration time in the chair for suitable indications. According to Merck, the subcutaneous candidate is already under regulatory review in several major markets, reflecting the group’s strategy to extend the reach and practicality of its highest-grossing therapy while preserving clinical performance comparable to the established IV standard.

How subcutaneous Keytruda changes the treatment day

Keytruda’s current IV regimen typically requires patients to spend a considerable block of time at infusion centers, which can strain hospital resources and disrupt work and family schedules, particularly for those on long-term immuno-oncology therapy. By moving to a subcutaneous route, Merck is targeting an injection that can be administered in minutes rather than the longer infusion sessions required for IV dosing, helping clinics turn over chairs faster and potentially easing backlogs in busy oncology units. In materials describing the subcutaneous development program, Merck emphasizes that the formulation still delivers pembrolizumab systemically, but through a shorter injection into subcutaneous tissue instead of a drip into a vein, with the regimen aligned as closely as possible to approved IV dosing schedules for overlapping tumor types. Clinical studies have been structured to show pharmacokinetic and efficacy comparability with IV Keytruda, because regulators in the US and Europe typically require demonstration that an alternative administration route provides similar exposure and outcomes before approving a switch or allowing substitution for established indications.

The convenience angle is particularly relevant in tumor types where patients receive Keytruda for extended periods or in combination with chemotherapy, since reducing infusion time could soften the cumulative treatment burden over multiple cycles. From a health-economics perspective, a subcutaneous option also opens the door to more flexible delivery models, such as administration in community practices or potentially in specialized home-care settings where local regulations and safety protocols permit. For healthcare systems under pressure to manage increasing oncology volumes, the ability to reallocate nursing time and infusion chairs from lengthy IV immunotherapy to other procedures can be a tangible operational benefit associated with the switch to a ready-to-inject format. On the patient side, the prospect of shorter clinic visits may improve adherence in some settings, especially where travel time to cancer centers is substantial or where caregivers must take time off work to accompany patients to appointments.

Merck’s development of a subcutaneous Keytruda also has a competitive dimension, as rival Bristol Myers Squibb pursues a similar strategy with a subcutaneous formulation of its own PD-1 inhibitor Opdivo. Both companies are investing in alternative delivery technologies and co-formulations with agents such as hyaluronidase to enable large-molecule monoclonal antibodies to be injected under the skin at clinically relevant doses. Industry analysts point out that these efforts are not only about patient convenience and clinic workflow, but also about product lifecycle management for franchises that are expected to face biosimilar or price-pressure challenges later this decade. In this context, a successfully launched subcutaneous Keytruda could help Merck differentiate its brand, maintain prescriber familiarity, and potentially slow switching to competing agents or future biosimilar pembrolizumab products, assuming the new route is well received by physicians and payers.

The regulatory path for subcutaneous Keytruda is happening against a changing US reimbursement backdrop. A proposed rule from the Centers for Medicare & Medicaid Services (CMS) would subject new subcutaneous formulations of drugs like Keytruda to Medicare drug price negotiations on a similar timeline as their original IV versions, rather than granting them a long period of separate treatment for pricing purposes. A recent analysis by BioPharma Dive noted that CMS explicitly signaled its intention to close what it describes as an “evergreening” loophole that could otherwise allow companies to prolong premium pricing via alternative formulations while the core molecule is already on the negotiation list. According to BioPharma Dive’s report on the draft CMS rule, under-the-skin versions of Keytruda and Opdivo would be treated as the same qualifying drugs as their IV counterparts for Medicare negotiations starting with the 2029 cycle. This means that even if the subcutaneous Keytruda secures regulatory approvals and uptake, Merck cannot count on it being shielded from upcoming US price ceilings solely by virtue of the new administration route.

Despite that policy headwind, Merck has made clear in presentations and earnings commentary that it sees formulation innovation as an important lever to sustain the Keytruda franchise over the coming years. Keytruda is already approved in dozens of indications worldwide, and the company continues to invest in new tumor settings and combinations with small molecules and other biologics, with the subcutaneous pathway adding another layer to that lifecycle strategy. Management has stated that the goal is to keep Keytruda clinically relevant well into the 2030s while transitioning the portfolio toward next-generation oncology and cardiometabolic candidates. For patients and clinicians, the near-term impact of a subcutaneous Keytruda, assuming approvals, will be felt primarily in day-to-day treatment logistics and patient experience rather than in headline-grabbing efficacy improvements, since the formulation is expected to match the IV product’s established performance in the labeled settings.

Strategically, the subcutaneous formulation offers Merck a way to defend share in core PD-1 indications and to respond to hospital and patient demand for more efficient care delivery, even as broader pricing reforms loom in the background. For investors, the project is one of several Keytruda lifecycle initiatives that will influence how smoothly Merck can manage the eventual plateau in revenue from its flagship and redeploy cash flow into newer assets, without making any single product update a make-or-break event for the company. Merck’s own news and pipeline communications emphasize that subcutaneous Keytruda sits alongside new indications, combinations and next-generation immuno-oncology agents in a broader strategy to diversify growth. Against that backdrop, the subcutaneous formulation is not a dramatic reinvention of Keytruda, but rather a practical evolution that reflects both clinical realities in oncology wards and growing policy scrutiny of how pharmaceutical companies extend the commercial lives of their biggest drugs.

Within Merck’s portfolio, Keytruda remains the central earnings driver, and a successful rollout of a subcutaneous option would likely help stabilize usage patterns in key markets even as biosimilar and negotiation risks increase over time. At the same time, US regulators’ move to align the treatment of subcutaneous and IV versions of high-cost biologics underscores that lifecycle moves centered on delivery convenience will not be immune from pricing pressure, limiting the extent to which formulation shifts can offset future negotiated discounts. As noted in a recent analysis of Merck’s situation under proposed Medicare drug price negotiations, policy changes aimed at drugs like Keytruda have already weighed on MRK’s share price as investors factor in lower long-term pricing power. Shares of Merck & Co. (US58933Y1055) traded on the NYSE at around $127 in recent sessions, reflecting a market that is balancing the company’s strong current Keytruda cash flows against regulatory and competitive challenges to its flagship cancer franchise.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.